GlassScriptPhysician profile
Steven Mates
NPI 1477923423
$120,884.31
in general payments reported to CMS, 2019-2025
15 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,077 · 2022: $8,875 · 2023: $27K · 2024: $32K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $22K · Honoraria: $18K · Food and Beverage: $11K · Travel and Lodging: $5,081 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,311.25 |
| Consulting Fee | $22,145.00 |
| Honoraria | $17,500.00 |
| Food and Beverage | $10,762.74 |
| Travel and Lodging | $5,080.78 |
| Education | $132.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $44,346.51 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $42,018.72 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $16,920.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,698.33 | 2021-2025 | Caplyta |
| Alkermes, INC. | $4,866.93 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $1,743.30 | 2021-2022 | |
| Lundbeck LLC | $1,200.94 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $831.60 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $820.40 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $568.20 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $478.27 | 2022-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $220.70 | 2022-2024 | Uzedy, Austedo Xr |
| Indivior INC. | $137.53 | 2022-2024 | Sublocade, Perseris |
| Tris Pharma INC | $20.41 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.